Cairo – Mubasher: Egyptian International Pharmaceutical Industries (EIPICO) posted an 18.7% year-on-year growth in its consolidated profits during the first quarter of 2019.

Net profits increased to EGP 218.31 million in the January-March period of 2019from EGP 183.97 million in the year-ago period, according to a statement to the Egyptian Exchange (EGX) on Wednesday.

Meanwhile, net sales surged to EGP 915.26 million in Q1-19, compared to EGP 732.08 million in Q1-18.

As for standalone business, EIPICO’s profits hiked to EGP 203.31 million in the three-month period ended 31 March, compared to EGP 172.66 million in the same period a year earlier.

For the full-year 2018, the EGX-listed firm’s net profits grew to EGP 701.31 million from EGP 688.87 million in the previous year, including minority shareholders’ rights.